Overall, in acromegaly, long-acting SSAs can achieve biochemical normalization of GH and IGF-I in 50% to 60% and often lead to modest tumor shrinkage.11, 12, 13, 14 Patients with AIP mutations have, however, significantly less tumor shrinkage and lower hormonal responses to first-generation SSAs.7 This evidence concerns the gene IGF1 and neoplasm.